Timeless Biosciences
Science-led.
Patient-driven.
Built at the intersection of microbiome science, systems biology, and oncology supportive care — with a founding vision to give patients a refund on lost time.
Nita Jain is the founder and CEO of Timeless Biosciences, where she leads scientific strategy and pipeline development for TB-001, the company's lead program targeting F. nucleatum-induced chemoresistance in colorectal cancer, with chemotherapy-induced GI toxicity as a secondary indication.
Her research background spans microbiome science, systems biology, and complex chronic illness, with a focus on how microbial metabolites regulate mucosal immunity, barrier integrity, and xenobiotic metabolism. She holds clinical trial advisory roles on the NIH RECOVER Initiative and Emory's REVERSE-LC study, and is a 2025 NIA Start-Up Challenge Finalist.
Her approach to drug development is systems-informed: examining how spatiotemporal and environmental factors shape molecular and metabolic disease pathology — and where a single, well-chosen intervention can change the trajectory of a complex system.
Adam Arterbery brings deep expertise spanning drug discovery, translational development, and IND strategy. A trained cellular and molecular biologist and immunologist, he has directed complex drug development initiatives across multiple indications, modalities, and delivery technologies, and has managed R&D, CMC, and regulatory programs throughout.
He has also led the development and training of AI and large language models across phenotype-genotype relationships in rare diseases, and advises on de-risking of capital deployment across the life sciences.
At Timeless Biosciences, Dr. Arterbery leads development of the discovery platform and multi-omics program — spanning metagenomics, metabolomics, metaproteomics, metatranscriptomics, and integrated bioinformatics pipelines.
Dr. DePaolo is a microbiome scientist with deep expertise in the gut-immune axis and its therapeutic implications. He served as Founding Director of the Center for Microbiome Sciences & Therapeutics at the University of Washington and as Chief Scientific Officer of Tend Health. He brings translational microbiome drug development experience directly to the TB-001 program.
Dr. Carter is a hematologist-oncologist and biotech founder. He is co-founder and Chief Scientific Officer of Otter Immuno-Oncology and previously co-founded Nora Therapeutics. His clinical experience in blood cancers and solid tumors, combined with a track record in early-stage company building, informs Timeless Biosciences' approach to endpoint design and development strategy.
Building our advisory network.
We are assembling a scientific advisory board of experts in GI oncology, microbiome science, clinical pharmacology, and drug development. Advisors will play an active role in shaping scientific and clinical strategy. If you are interested in engaging, please reach out.